Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ABEO, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Non-conforming pz-cel surgical applicati | Epidermolysis Bullosa (EB) | Phase 4 · NCT07717736 | Not yet recruiting |
| Pz-cel surgical application to DEB wound | Epidermolysis Bullosa (EB) | Phase 4 · NCT07717736 | Not yet recruiting |
| EB-101 | Epidermolysis Bullosa | Phase 3 · NCT04227106 | Completed |
| EB-101 Surgical application of RDEB woun | Epidermolysis Bullosa | Phase 3 · NCT05725018 | Active not recruiting |
| MSI-78 | Diabetic Foot Ulcers | Phase 3 · NCT00563394 | Completed |
| Optimized Prophylactic IM Therapy | MPS IIIA | Phase 2/3 · NCT02716246 | Recruiting |
| Prophylactic Immunomodulatory (IM) Thera | MPS IIIA | Phase 2/3 · NCT02716246 | Recruiting |
| Rebisufligene Etisparvovec | MPS IIIA | Phase 2/3 · NCT02716246 | Recruiting |
| ABO-102 | MPS IIIA | Phase 1/2 · NCT04088734 | Terminated |
| Econazole | Onychomycosis | Phase 2 · NCT00385502 | Completed |
| LZRSE-Col7A1 Engineered Autologous Epide | Epidermolysis Bullosa Dystrophica | Phase 1/2 · NCT01263379 | Completed |
| rAAV9.CMV.hNAGLU | Mucopolysaccharidosis Type 3 B | Phase 1/2 · NCT03315182 | Terminated |
| ABO-101 | Mucopolysaccharidosis III-B | N/A · NCT04655911 | Terminated |
Also used in these trials (approved or third-party drugs, not ABEO's own candidates): Adjuvant IM Therapy, Ofloxacin Otic.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ABEO holds $146.8M in cash and short-term investments (as of Jun 30, 2026) and burns about $18.7M/quarter from operations, an estimated runway of 23.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 40 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ABEO files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | Institution (13G, 5%+) | 5,775,350 | 10.10% | 2026-03-31 |
| Blackrock Inc. | Institution (13F) | 3,352,474 | 5.86% | 2026-06-30 |
| NANTAHALA CAPITAL PARTNERS LIMITED PARTN | 5%+ holder (13G) | 3,333,757 | 5.83% | 2026-03-31 |
| Orin Hirschman | Institution (13G, 5%+) | 3,100,000 | 5.42% | 2026-03-31 |
| Funicular Funds, LP | 5%+ holder (13G) | 3,007,329 | 5.26% | 2026-03-27 |
| Cable Car Capital, LP | Institution (13F) | 3,007,329 | 5.26% | 2026-06-30 |
| AIGH Capital Management LLC | Institution (13F) | 2,987,000 | 5.22% | 2026-06-30 |
| Daniel Kaufman | 5%+ holder (13G) | 2,943,629 | 5.15% | 2026-03-26 |
| Vanguard Capital Management LLC | Institution (13F) | 2,211,433 | 3.87% | 2026-06-30 |
| OneDigital Investment Advisors LLC | Institution (13F) | 1,653,024 | 2.89% | 2026-06-30 |
| AWM Investment Company, Inc. | Institution (13F) | 1,486,130 | 2.60% | 2026-06-30 |
| Vishwas Seshadri Chief Executive Officer, Director |
Insider | 1,286,500 | 2.25% | 2026-09-29 |
Share count 57,184,017 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-09-29 filed 2026-09-29 |
O'Malley Brendan M. |
Sale (S) | 6,727 | $5.16 | 421,226 |
| 2026-09-29 filed 2026-09-29 |
Seshadri Vishwas |
Sale (S) | 19,608 | $5.16 | 1,286,500 |
| 2026-09-29 filed 2026-09-29 |
Vazzano Joseph Walter |
Sale (S) | 9,191 | $5.16 | 482,888 |
| 2026-09-29 filed 2026-09-29 |
Vasanthavada Madhav |
Sale (S) | 4,902 | $5.16 | 285,721 |
| 2026-09-01 filed 2026-09-01 |
Alvino Mark |
Sale (S) | 15,000 | $5.86 | 62,065 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABEO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →